Catherine Wood's IONS Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 422,968 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $33.46 M, representing 0.22% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 37 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2021, adding 3.77 M shares. Largest reduction occurred in Q2 2022, reducing 1.47 M shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -208,247 | Reduce 32.99% | 422,968 | $79.11 |
| Q3 2025 | -269,103 | Reduce 29.89% | 631,215 | $65.42 |
| Q2 2025 | -100,209 | Reduce 10.02% | 900,318 | $39.51 |
| Q1 2025 | -24,733 | Reduce 2.41% | 1 M | $30.17 |
| Q4 2024 | -359,009 | Reduce 25.93% | 1.03 M | $34.96 |
| Q3 2024 | +23,244 | Add 1.71% | 1.38 M | $40.06 |
| Q2 2024 | -38,827 | Reduce 2.77% | 1.36 M | $47.66 |
| Q1 2024 | -505,204 | Reduce 26.52% | 1.4 M | $43.35 |
| Q4 2023 | -461,311 | Reduce 19.49% | 1.91 M | $50.59 |
| Q3 2023 | -56,264 | Reduce 2.32% | 2.37 M | $45.36 |
| Q2 2023 | -214,561 | Reduce 8.14% | 2.42 M | $41.03 |
| Q1 2023 | -36,346 | Reduce 1.36% | 2.64 M | $35.74 |
| Q4 2022 | -1.04 M | Reduce 28.00% | 2.67 M | $37.77 |
| Q3 2022 | -988,190 | Reduce 21.02% | 3.71 M | $44.23 |
| Q2 2022 | -1.47 M | Reduce 23.82% | 4.7 M | $36.52 |
| Q1 2022 | -911,948 | Reduce 12.87% | 6.17 M | $37.04 |
| Q4 2021 | -1.43 M | Reduce 16.78% | 7.08 M | $30.43 |
| Q3 2021 | -396,349 | Reduce 4.45% | 8.51 M | $33.54 |
| Q2 2021 | +3.77 M | Add 73.23% | 8.91 M | $39.89 |
| Q1 2021 | +2.74 M | Add 114.30% | 5.14 M | $44.96 |
| Q4 2020 | +1.9 M | Add 377.47% | 2.4 M | $56.54 |
| Q3 2020 | +158,429 | Add 46.04% | 502,560 | $47.45 |
| Q2 2020 | +224,450 | Add 187.54% | 344,131 | $58.96 |
| Q1 2020 | -96,344 | Reduce 44.60% | 119,681 | $47.28 |
| Q4 2019 | +19,356 | Add 9.84% | 216,025 | $60.41 |
| Q3 2019 | +38,896 | Add 24.65% | 196,669 | $59.91 |
| Q2 2019 | -7,205 | Reduce 4.37% | 157,773 | $64.27 |
| Q1 2019 | -77,334 | Reduce 31.92% | 164,978 | $81.17 |
| Q4 2018 | +12,994 | Add 5.67% | 242,312 | $54.06 |
| Q3 2018 | +16,191 | Add 7.60% | 229,318 | $51.58 |
| Q2 2018 | -138,778 | Reduce 39.44% | 213,127 | $41.67 |
| Q1 2018 | -18,930 | Reduce 5.10% | 351,905 | $44.08 |
| Q4 2017 | +370,836 | Add 0.00% | 370,835 | $50.30 |
| Q2 2017 | +49,428 | Add 38.75% | 176,991 | $50.87 |
| Q1 2017 | +120,942 | Add 1826.64% | 127,563 | $40.20 |
| Q4 2016 | +6,622 | Add 0.00% | 6,621 | $47.88 |
Catherine Wood's Ionis Pharmaceuticals Investment FAQs
Catherine Wood first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2016, acquiring 6,621 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Ionis Pharmaceuticals, Inc. (IONS) for 37 quarters since Q4 2016.
Catherine Wood's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q2 2021, adding 8,907,733 shares worth $355.33 M.
According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 422,968 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $33.46 M.
As of the Q4 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.22% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 8,907,733 shares, as reported at the end of Q2 2021.